Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
BMJ Global Health(1)
Diabetes Care(1)
European Heart Journal(1)
Heart(1)
New England Journal of Medicine(1)
Área temáticas
Enfermedades(6)
Farmacología y terapéutica(3)
Problemas sociales y servicios a grupos(2)
Biblioteconomía y Documentación informatica(1)
Fisiología humana(1)
Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries
ArticleAbstract: Objectives We aimed to examine the relationship between access to medicine for cardiovascular diseasPalabras claves:epidemiology, Health policy, prevention strategies, PUBLIC HEALTH, TreatmentAutores:Alhabib K.F., Avezum A.J., Bahonar A., Chifamba J., Chow C.K., Dans A.M., DIaz R., Gulec S., Gupta R., Hu B., Kazmi K., Khatib R., Kruger L., Kumar R., Lanas F.T., Lear S.A., Li W., Marschner S., Mckee M., Mony P.K., Nguyen T.N., PATRICIO LOPEZ -JARAMILLO, Rahman O., Rangarajan S., Rosengren A., Teo K.K., Yeates K.E., Yusoff K., Yusuf S., Yusufali A.M., Zatońska K.Fuentes:googlescopusAntihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria
ArticleAbstract: Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation-3) found that antihypPalabras claves:Blood pressure, candesartan, Cardiovascular disease, Lipoprotein, Primary Prevention, statinAutores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Gao P., Hart R.G., Held C., Khunti K., Leiter L.A., Lewis B.S., Lonn E.M., Pais P., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Reid C.M., Sliwa K., Toff W.D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusContrasting associations between diabetes and cardiovascular mortality rates in low-, middle-, and high-income countries: Cohort study data from 143,567 individuals in 21 countries in the pure study
ArticleAbstract: OBJECTIVE We aimed to compare cardiovascular (CV) events, all-cause mortality, and CV mortality ratePalabras claves:Autores:Alhabib K.F., Anjana R.M., Avezum A.J., Bahonar A., Chifamba J., Dagenais G.R., DIaz R., Gerstein H.C., Gupta R., Hu L., Iqbal R., Iype T., Karsidag K., Kruger L., Lakshmi P.V.M., Lanas F.T., Lear S.A., Mohan V., Mony P.K., Noorhassim I., Palileo-Villanueva L.M., PATRICIO LOPEZ -JARAMILLO, Rahman M.O., Rangarajan S., Rosengren A., Sheridan P., Teo K.K., Venkatesan U., Wei L., Yeates K.E., Yusoff K., Yusuf S., Yusufali A.M., Zatońska K.Fuentes:googlescopusErratum: ‘Corrigendum to “Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study” [Sleep Medicine 80 (2021) 265–272]’ (Sleep Medicine (2021) 80 (265–272), (S1389945721000745), (10.1016/j.sleep.2021.01.057))
OtherAbstract: The authors regret < Co-author Sadi Gulec (Ankara University School of Medicine, Ankara, Turkey) wasPalabras claves:Autores:Abat M.E.M., Alhabib K.F., Avezum A.J., Bahonar A., Bangdiwala S.I., Chifamba J., DIaz R., Gulec S., Gupta R., Hu B., Iqbal R., Kruger L., Lanas F.T., Lear S.A., Mohan V., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Rosengren A., Soman B., Wang C., Wei L., Yeates K.E., Yusoff K., Yusuf S., Yusufali A.M., Zatońska K.Fuentes:scopusLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusVariations in knowledge, awareness and treatment of hypertension and stroke risk by country income level
ArticleAbstract: Objective Hypertension is the most important modifiable risk factor for stroke globally. We hypothesPalabras claves:epidemiology, Hypertension, strokeAutores:Alhussain F., Avezum A.J., Chin S.L., Czlonkowska A., Daliwonga M., Damasceno A., Dans A.M., DIaz R., Diener H.C., ElSayed A., Ferguson J., Hankey G.J., Iqbal R., Iversen H.K., Judge C., Lanas F.T., Langhorne P., Lisheng L., Málaga G., Mondo C.K., Nilanont Y., Ogah O.S., Ogunniyi A., Oguz A., Oveisgharan S., O’Donnell M., Pais P., PATRICIO LOPEZ -JARAMILLO, Peñaherrera E., Pogosova N., Rangarajan S., Rao-Melacini P., Rosengren A., Rumboldt Z., Ryglewicz D., Smyth A., Wang X., Weimar C., Xavier D., Yusoff K., Yusuf S., Yusufali A.M., Zhang H.Fuentes:googlescopusVitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial
ArticleAbstract: Background and aims: Vitamin D has mostly been tested in Western populations. We examined the effectPalabras claves:Cáncer, Cardiovascular disease, death, Falls, fractures, vitamin DAutores:Bosch J., Christou C., Dagenais G.R., Dans A.M., Gamra H., Gao P., Joseph P.G., Pais P., PATRICIO LOPEZ -JARAMILLO, Santoso A., Talukder S.H., Teo K., Tyrwhitt J., Xavier D., Yusoff K., Yusuf S.Fuentes:googlescopusPolypill with or without aspirin in persons without cardiovascular disease
ArticleAbstract: BACKGROUND A polypill comprising statins, multiple blood-pressure-lowering drugs, and aspirin has bePalabras claves:Autores:Bosch J.J., Christou C., Dagenais G.R., Dans A.M., Gamra H., Gao P., Girish P., Joseph P.G., McCready T., Pais P., PATRICIO LOPEZ -JARAMILLO, Rocha C., Santoso A., Talukder S.H., Teo K.K., Tyrwhitt J., Xavier D., Xavier F., Yeates K.E., Yusoff K., Yusuf S.Fuentes:googlescopus